PT-141 vs Melanotan II: Research Comparison | Peptide Intel Hub

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist selective for MC3R and MC4R. The MC4R activation is the proposed mechanism for the CNS-mediated effects in published research; the MC1R activity that drives pigmentation is minimised by design.

Melanotan II is a cyclic heptapeptide agonist at MC1, MC3, MC4 and MC5. The broad receptor profile is the reason Melanotan II is used in pigmentation-axis research — MC1R activity drives the melanogenesis signal — but also the reason it produces the wider off-target profile PT-141 was engineered to avoid.

PT-141 is selective for MC3R and MC4R — a narrow melanocortin research tool for isolating the MC4R-driven CNS-axis effects from the MC1R-driven pigmentation axis.

Melanotan II is a broad melanocortin agonist. It is the reference research tool for MC1R-mediated melanogenesis studies, but the broader receptor engagement produces a wider off-target profile in CNS, appetite and cardiovascular axes.

PT-141 has a short-to-medium research half-life; typical research cadences are per-experiment single-dose or intermittent rather than chronic. The cyclic structure improves stability over linear melanocortin peptides.

Melanotan II has a similar short half-life and cyclic-peptide stability profile. Research cadences vary widely depending on whether pigmentation-axis or acute CNS-axis endpoints are being measured.

PT-141 is used in CNS melanocortin-axis research — particularly MC4R-driven signalling — where the pigmentation axis is a confound to be avoided. The receptor-selective profile makes it a cleaner research tool for isolating MC4R effects.

Melanotan II is used in pigmentation-axis research (MC1R melanogenesis), in broad melanocortin-axis studies, and as the reference broad-spectrum comparator when a wider receptor engagement is central to the experimental design.

Both PT-141 and Melanotan II should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both PT-141 and Melanotan II benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose PT-141 when the protocol requires MC3R / MC4R selective activation and needs to avoid MC1R pigmentation-axis confounds. Researchers choose Melanotan II when broad-spectrum melanocortin activation is the experimental requirement — pigmentation research, MC1R melanogenesis models, or when a broad melanocortin comparator arm is needed. Matched panels sometimes include both compounds to isolate the receptor-selectivity contribution.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both PT-141 and Melanotan II against a project timeline so the experimental panel is sourced under a single analytical specification window.

Bremelanotide, known commercially as Vyleesi™, represents a focused therapeutic development for addressing hypoactive sexual desire disorder (HSDD) in premenopausal women (PMID 31429064). This condition is characterized by a deficiency of sexual thoughts, feelings, or receptiveness to sexual stimulation that has persisted for at least six months and causes personal distress, unrelated to other medical conditions (PMID 34510696). Bremelanotide is administered as a self-administered, on-demand subcutaneous injection, typically approximately 45 minutes prior to sexual activity (PMID 31429064, PMID 31893927). It is the second medication approved by the US Food and Drug Administration (FDA) for the treatment of HSDD (PMID 31893927, PMID 33455598).

Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) (PMID 31429064). Its mechanism of action involves acting as a melanocortin receptor (MCR) agonist, specifically with high affinity for the melanocortin type 4 receptor (MC4R) (PMID 31429064, PMID 33455598). MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus in the brain, a region considered important for female sexual function (PMID 33455598). It is hypothesized that bremelanotide, by activating these presynaptic MC4Rs on neurons in the mPOA, leads to an increased release of dopamine, an excitatory neurotransmitter associated with increased sexual desire (PMID 33455598). This suggests that bremelanotide may modulate brain pathways involved in sexual response (PMID 31429064).

The regulation of central melanocortin signaling is thought to enhance sexual desire (PMID 36242769). Bremelanotide's role as a melanocortin receptor agonist has led to the hypothesis that it can trigger excitatory brain pathways in premenopausal women with HSDD (PMID 36242769). The neurobiology of HSDD itself is suggested to involve an imbalance of hormone and neurotransmitter levels in the brain, potentially resulting in decreased excitation, increased inhibition, or a combination of both (PMID 33455598). Neurotransmitters such as dopamine, norepinephrine, and serotonin, alongside hormones like estradiol and testosterone, are believed to contribute to female sexual desire and response (PMID 33455598).

Clinical trials of bremelanotide have demonstrated statistically significant improvements in desire and a significant reduction in distress related to a lack of desire in women with HSDD (PMID 31893927, PMID 36242769). However, several reports suggest that the overall clinical benefit may be modest (PMID 31893927, PMID 36242769). One analysis of the phase III 'RECONNECT' trials indicated that bremelanotide's benefits were statistically modest and limited to outcomes for which there is scant evidence of validity among women with HSDD (PMID 36809187). Furthermore, it was noted that effect sizes for previously unpublished efficacy outcomes ranged from nil to small (PMID 36809187).

Concerns have been raised regarding the measurement properties and reporting of efficacy outcomes in the bremelanotide trials. Continuous efficacy outcomes, such as the Female Sexual Function Index (FSFI) and its Desire domain (FSFI-D), and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and its item assessing distress due to low desire (FSDS-DAO #13), have been cited as having, at best, questionable validity evidence for women with HSDD (PMID 36809187). There was also an absence of validity evidence for previously published categorical treatment response outcomes from the RECONNECT trials (PMID 36809187). A re-analysis of the phase III trials indicated that a significant portion of protocol-listed outcomes were not reported, and several secondary measures, which were not listed in the study protocols, were presented without a stated rationale or cited evidence of validity (PMID 33678061). This re-analysis concluded that bremelanotide's modest benefits on incompletely reported, post-hoc measures of questionable validity, combined with participants preferring placebo, suggest the drug is generally not useful (PMID 33678061).

Bremelanotide appears to be moderately safe and well-tolerated (PMID 36242769). The clinical development program for bremelanotide included 3500 subjects across 43 completed studies, with subjects in phase 3 studies using the drug for up to 18 months (PMID 35147466). The most common adverse effects (AEs) reported in the integrated double-blind portion of the phase 3 studies (N=1247) were nausea (40.0% vs. 1.3% for placebo), facial flushing (20.3% vs. 1.3% for placebo), headache (11.3% vs. 1.9% for placebo), and injection site reactions (5.4% vs. 0.5% for placebo) (PMID 31893927, PMID 35147466, PMID 36242769). Nausea was the most frequent reason for discontinuing bremelanotide in these trials (PMID 35147466).

Other safety considerations include the observation of small and transient, yet statistically significant, blood pressure increases during ambulatory blood pressure monitoring (PMID 35147466). While not considered clinically important, caution is advised for patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment (PMID 35147466). Focal hyperpigmentation was rare when bremelanotide was dosed according to label recommendations, but it occurred in over one-third of subjects who received up to 16 consecutive daily doses (PMID 35147466). Bremelanotide has limited drug-drug interactions, with no clinically significant interactions observed with ethanol (PMID 31893927). However, interactions that lowered plasma concentrations of indomethacin and naltrexone were noted (PMID 35147466). There were no deaths reported in the clinical development program, and only a few subjects experienced serious adverse events (PMID 35147466). Prescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month (PMID 31893927).

Melanotan II (MT-II) is a cyclic truncated peptide, similar to bremelanotide, and also functions as a non-selective melanocortin-receptor agonist (PMID 16412534, PMID 31953620). Historically, it has been clinically studied for its potential in inducing skin tanning and for the diagnosis and treatment of male erectile dysfunction (PMID 16412534). Unlike bremelanotide, which is FDA-approved, Melanotan II is an unlicensed substance, and its sale is illegal in the United Kingdom and many other countries (PMID 40210573).

Evidence from animal studies indicates a broader range of effects for MT-II than those described for bremelanotide. In zebrafish, MT-II was found to reverse memory impairment, elevated anxiety levels, and reduced exploratory propensity induced by a short-term high-fat (HF) diet (PMID 37478579). In a maternal immune activation (MIA) mouse model of autism, continuous administration of MT-II over a seven-day course rescued autism-like social behavioral deficits in adult male mice (PMID 30629642). It also partially rescued the impaired thermogenic capacity in pituitary adenylate cyclase-activating polypeptide (PACAP) deficient mice during cold acclimation, suggesting a role in regulating sympathetic nerve activity to brown adipose tissue (PMID 33332767). These studies were conducted in animal models and not human subjects.

The use of Melanotan II in humans has been associated with significant adverse effects and health risks. Renal infarction, an uncommon and potentially life-threatening condition resulting from acute disruption of renal blood flow, has been reported as a possible consequence of Melanotan II use (PMID 31953620). The mechanism of renal injury might involve thrombotic pharmacological influence and a possible direct toxic effect on renal parenchyma (PMID 31953620). Rhabdomyolysis and renal failure have also been described in conjunction with Melanotan II (PMID 31953620).

A particularly serious concern linked to Melanotan II is its potential association with malignant melanoma. A case report detailed a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II nasal spray for tanning purposes, which was subsequently diagnosed as mucosal malignant melanoma (PMID 40210573). This highlights the need for awareness of serious side effects, especially given that it is often used as a tanning agent (PMID 40210573, PMID 16412534). While normal background C57 male mice treated with MT-II showed no significant alteration in social behavioral metrics or anxiety-like/repetitive behaviors, they did exhibit significant weight loss following subacute treatment (PMID 30629642).

The clinical and commercial trajectories of bremelanotide and melanotan II have diverged significantly. Bremelanotide has achieved FDA approval for a specific medical indication—HSDD in premenopausal women—following rigorous phase 2 and 3 clinical trials (PMID 31893927, PMID 31429064). Its development was spearheaded by Palatin Technologies, who later out-licensed it to AMAG Pharmaceuticals Inc. for commercialization in North America (PMID 31429064). This path has led to it being a prescribed medication, with established guidelines for administration and monitoring (PMID 31893927, PMID 35147466).

In contrast, Melanotan II, while patented and subject to clinical studies for applications like tanning and male erectile dysfunction (PMID 16412534), has not achieved regulatory approval as a legitimate therapeutic agent in many jurisdictions. It is explicitly noted as unlicensed and illegal for sale in various countries, including the United Kingdom (PMID 40210573). This distinction underscores the differing levels of scrutiny, safety testing, and evidence required for market authorization, positioning bremelanotide as a regulated pharmaceutical product and Melanotan II as an unregulated substance with known health risks (PMID 40210573, PMID 31953620).

Both bremelanotide and melanotan II are melanocortin peptide analogues, designed to interact with melanocortin receptors (PMID 31429064, PMID 16412534). The melanocortins are a family of multifunctional peptidergic hormones, and superpotent, prolonged-acting, enzymatically resistant analogues have been developed to elucidate the role of melanocortins and their receptors in physiological functions (PMID 16412534). Bremelanotide is an MCR agonist that nonselectively activates several receptor subtypes, with MC4R being the most relevant at therapeutic doses for HSDD (PMID 33455598). Melanotan II is described as a non-selective melanocortin-receptor agonist (PMID 31953620).

While both peptides target the melanocortin system, their specific applications and the extent of their validated therapeutic benefits differ substantially. Bremelanotide's development has been tightly focused on a single, FDA-approved indication—HSDD in women (PMID 31429064). The evidence base for bremelanotide, while subject to scrutiny regarding clinical significance and measurement validity, is derived from human phase 3 clinical trials (PMID 36809187, PMID 31893927). Melanotan II, on the other hand, shows a range of effects in animal models related to memory, anxiety, autism-like features, and thermogenesis (PMID 37478579, PMID 30629642, PMID 33332767). In human contexts, its noted effects include increasing skin pigmentation and producing spontaneous penile erection and sexual stimulation (PMID 31953620, PMID 16412534). However, unlike bremelanotide, these human applications are often associated with unregulated use and serious health risks, particularly concerning renal injury and potential for malignant melanoma (PMID 31953620, PMID 40210573).

• Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. — The Annals of pharmacotherapy (2020). PMID 31893927
• Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. — Journal of sex research (2024). PMID 36809187
• Bremelanotide: First Approval. — Drugs (2019). PMID 31429064
• Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. — Journal of midwifery & women's health (2021). PMID 34510696
• An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. — Expert opinion on pharmacotherapy (2023). PMID 36242769
• The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. — CNS spectrums (2022). PMID 33455598
• Safety Profile of Bremelanotide Across the Clinical Development Program. — Journal of women's health (2002) (2022). PMID 35147466
• Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. — Journal of sex research (2021). PMID 33678061
• Melanotan-II reverses memory impairment induced by a short-term HF diet. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023). PMID 37478579
• Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. — PloS one (2019). PMID 30629642
• Melanotan II: a possible cause of renal infarction: review of the literature and case report. — CEN case reports (2020). PMID 31953620
• Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — International journal of oral and maxillofacial surgery (2025). PMID 40210573
• Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice. — Experimental physiology (2021). PMID 33332767
• Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. — Peptides (2006). PMID 16412534

Both PT-141 and Melanotan II are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.